

Mark C Markowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8512453/publications.pdf>

Version: 2024-02-01

37
papers

914
citations

471509

17
h-index

477307

29
g-index

39
all docs

39
docs citations

39
times ranked

1492
citing authors

#	ARTICLE	IF	CITATIONS
1	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 248-252.	5.0	13
2	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 97-101.	1.9	14
3	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸ F-DCFPyL. <i>Molecular Imaging</i> , 2022, 2022, 7056983.	1.4	6
4	Bipolar androgen therapy (BAT): A patient's guide. <i>Prostate</i> , 2022, 82, 753-762.	2.3	6
5	A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor-targeting Agent. <i>Clinical Cancer Research</i> , 2022, 28, 2789-2795.	7.0	17
6	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. <i>European Urology Open Science</i> , 2022, 41, 112-115.	0.4	4
7	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021, 79, 692-699.	1.9	49
8	Detection of Early Progression with ¹⁸ F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1270-1273.	5.0	6
9	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021, 80, 632-640.	1.9	61
10	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted ¹⁸ F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1430-1437.	5.0	24
11	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021, 144, 302-309.	2.8	29
12	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382.	1.6	65
13	Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs. , 2021, , .		0
14	Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes. <i>Urology</i> , 2021, 154, 201-207.	1.0	5
15	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. <i>Journal of Urology</i> , 2021, 206, 623-629.	0.4	4
16	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 5948-5962.	0.9	30
17	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz093.	2.9	126
18	<i>BRCA1</i> Versus <i>BRCA2</i> and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3735-3739.	1.6	38

#	ARTICLE	IF	CITATIONS
19	PARP inhibitors in prostate cancer: time to narrow patient selection?. Expert Review of Anticancer Therapy, 2020, 20, 523-526.	2.4	4
20	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). BMC Cancer, 2020, 20, 492.	2.6	16
21	Advanced renal cell carcinoma and COVID-19 – a personal perspective. Nature Reviews Urology, 2020, 17, 425-427.	3.8	10
22	Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate, 2020, 80, 407-411.	2.3	24
23	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. Journal of Urology, 2020, 204, 496-502.	0.4	12
24	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.8	37
25	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, 470-475.e1.	1.9	26
26	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	2.6	3
27	Cutaneous finger and tongue metastases in renal cell carcinoma. BMJ Case Reports, 2019, 12, e230516.	0.5	2
28	Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT. Molecular Imaging and Biology, 2019, 21, 567-573.	2.6	46
29	The Microbiome and Genitourinary Cancer: A Collaborative Review. European Urology, 2019, 75, 637-646.	1.9	103
30	Germline Genetic Testing in Prostate Cancer – Further Enrichment in Variant Histologies?. Oncoscience, 2018, 5, 62-64.	2.2	7
31	Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate. Prostate, 2018, 78, 992-1000.	2.3	4
32	Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report. Clinical Genitourinary Cancer, 2017, 15, e839-e842.	1.9	4
33	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Expert Opinion on Investigational Drugs, 2017, 26, 1391-1397.	4.1	26
34	Early use of chemotherapy in metastatic prostate cancer. Cancer Treatment Reviews, 2017, 55, 218-224.	7.7	19
35	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	3.0	42
36	Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e417-e422.	1.9	0

#	ARTICLE	IF	CITATIONS
37	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , 2016, 76, 1484-1490.	2.3	29